Green Valley ceased production of its self-developed sodium oligomannate capsules and will close the related office and production areas, as the registration certificate for the Alzheimer's disease treatment expired, the Chinese pharmaceutical firm told Yicai yesterday. Green Valley has been withstanding severe operational pressure, and its cash flow is extremely tight.